Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07459647 · ClinicalTrials.gov registry record · Phase 2
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
A Phase 2 study, sponsored by MapLight Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
NCT07459647: Recruiting Phase 2 study, sponsored by MapLight Therapeutics.
NCT07459647 is a Phase 2 study that is actively recruiting participants, run by MapLight Therapeutics. The registered enrollment target is 500 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07459647, a Phase 2 study, is actively recruiting participants, sponsored by MapLight Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
Study Summary
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
Primary Outcome
using the incidence of TEAEs, TE-SAEs, and TEAEs leading to study discontinuation.
Interventions
- DRUG ML-007C-MA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2030-02 |
| Phase | Phase 2 |
What NCT07459647 shows while recruiting
NCT07459647 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher).
The record links to 0 conditions, and to 1 intervention - of which ML-007C-MA is the first listed.
NCT07459647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07459647 about?
NCT07459647 is a clinical study titled "A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia". ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
What is the current status of trial NCT07459647?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2026-03-31. Estimated completion is 2030-02.
What interventions are being tested in trial NCT07459647?
The interventions under investigation include: ML-007C-MA (DRUG).
Who is sponsoring clinical trial NCT07459647?
This trial is sponsored by MapLight Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07459647's enrollment target sits among peer trials
500 70th of 2000 higher than 1,927 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI